Allovir Inc expected to post a loss of 44 cents a share - Earnings Preview

Kalaris Therapeutics

31/07/2023 19:35

* Allovir Inc  ALVR.OQ   ALVR.O  is expected to show no
change in
quarterly revenue when it reports  results on August 2
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Allovir Inc is for
a loss
of 44 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Allovir Inc
is
$20​, above​ its last closing price of $3.00. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.46       -0.46      -0.44     Beat    4.3
 Dec. 31 2023  -0.56       -0.54      -0.37     Beat    31.9
 Sep. 30 2022  -0.52       -0.53      -0.50     Beat    5.1​
 Jun. 30 2022  -0.73       -0.73      -0.69     Beat    5.5
 ​​Mar.        -0.80       -0.80      -0.69     Beat    13.4
 31 2022                                                
 Dec. 31 2021  -0.78       -0.81      -0.92     Missed  -13.1​
 Sep. 30 2021  -0.58       -0.55      -0.72     Missed  -30.9
 Jun. 30 2021  -0.54       -0.49      -0.60     Missed  -22.4
 This summary was machine generated July 31 at 18:34 GMT.  All
figures in US dollars  unless otherwise stated